AU2020409429B2 - Compounds - Google Patents

Compounds

Info

Publication number
AU2020409429B2
AU2020409429B2 AU2020409429A AU2020409429A AU2020409429B2 AU 2020409429 B2 AU2020409429 B2 AU 2020409429B2 AU 2020409429 A AU2020409429 A AU 2020409429A AU 2020409429 A AU2020409429 A AU 2020409429A AU 2020409429 B2 AU2020409429 B2 AU 2020409429B2
Authority
AU
Australia
Prior art keywords
benzo
methoxy
imidazole
ethane
diyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020409429A
Other languages
English (en)
Other versions
AU2020409429A1 (en
Inventor
Michelle Ang CAMERINO
Anthony Nicholas Cuzzupe
Matthew Lloyd DENNIS
Jonathan Grant Hubert
Benjamin Joseph MORROW
Paul Anthony Stupple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTXT Pty Ltd
Original Assignee
CTXT Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1918761.6A external-priority patent/GB201918761D0/en
Priority claimed from GBGB2009944.6A external-priority patent/GB202009944D0/en
Application filed by CTXT Pty Ltd filed Critical CTXT Pty Ltd
Publication of AU2020409429A1 publication Critical patent/AU2020409429A1/en
Assigned to CTXT PTY LTD reassignment CTXT PTY LTD Amend patent request/document other than specification (104) Assignors: CTXT PTY LIMITED
Application granted granted Critical
Publication of AU2020409429B2 publication Critical patent/AU2020409429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020409429A 2019-12-18 2020-12-18 Compounds Active AU2020409429B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1918761.6A GB201918761D0 (en) 2019-12-18 2019-12-18 Compounds
GB1918761.6 2019-12-18
GB2009944.6 2020-06-30
GBGB2009944.6A GB202009944D0 (en) 2020-06-30 2020-06-30 Compounds
PCT/AU2020/051394 WO2021119753A1 (en) 2019-12-18 2020-12-18 Compounds

Publications (2)

Publication Number Publication Date
AU2020409429A1 AU2020409429A1 (en) 2022-06-16
AU2020409429B2 true AU2020409429B2 (en) 2026-07-23

Family

ID=76476453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020409429A Active AU2020409429B2 (en) 2019-12-18 2020-12-18 Compounds

Country Status (8)

Country Link
US (2) US12415785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4077318B1 (cg-RX-API-DMAC7.html)
JP (3) JP7662644B2 (cg-RX-API-DMAC7.html)
CN (1) CN114981265B (cg-RX-API-DMAC7.html)
AU (1) AU2020409429B2 (cg-RX-API-DMAC7.html)
CA (1) CA3164751A1 (cg-RX-API-DMAC7.html)
ES (1) ES3056923T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021119753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022266711A1 (en) * 2021-06-23 2022-12-29 Aculeus Therapeutics Pty Ltd Substituted amidobenzimidazole dimers as sting modulators
CN113603661B (zh) * 2021-08-11 2024-04-09 沈阳药科大学 (s)-5-氟-3-甲基异苯并呋喃-3-酮的合成方法
CN114349662A (zh) * 2022-01-20 2022-04-15 杭州裕普润生物科技有限公司 一种溴化苄的制备方法
CN114671747B (zh) * 2022-04-08 2024-10-29 浙江永太科技股份有限公司 一种4-氯-2-氟苯甲醛的合成方法
US20260191834A1 (en) * 2022-11-09 2026-07-09 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma
WO2024174863A1 (zh) * 2023-02-22 2024-08-29 深圳众格生物科技有限公司 Sting激动剂及其制备方法和医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5414010A (en) * 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2417806C (en) 2000-08-04 2011-05-10 Corixa Corporation New immunoeffector compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
TW200418848A (en) 2002-10-24 2004-10-01 Glaxo Group Ltd Compounds
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
ES2298627T3 (es) 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
EP1581530A1 (en) 2002-12-13 2005-10-05 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1748991A1 (en) 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2361845T3 (es) 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
LT2609118T (lt) 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
KR102023661B1 (ko) 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 抗ox40抗体およびそれを使用する方法
AU2013256468A1 (en) 2012-04-30 2014-12-04 Glen N. Barber Modulating immune responses
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. STINGアゴニストとしてのベンゾ[b]チオフェン化合物
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
GB2563642A (en) 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
US11377440B2 (en) * 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CN110016025B (zh) 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3802534B1 (en) * 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Also Published As

Publication number Publication date
ES3056923T3 (en) 2026-02-25
EP4077318B1 (en) 2025-10-15
US12415785B2 (en) 2025-09-16
EP4077318A1 (en) 2022-10-26
US20230062932A1 (en) 2023-03-02
CN114981265B (zh) 2025-01-03
CN114981265A (zh) 2022-08-30
WO2021119753A1 (en) 2021-06-24
CA3164751A1 (en) 2021-06-24
US20260132112A1 (en) 2026-05-14
JP2025061311A (ja) 2025-04-10
JP7662644B2 (ja) 2025-04-15
EP4077318A4 (en) 2023-11-22
AU2020409429A1 (en) 2022-06-16
JP2026116400A (ja) 2026-07-09
JP2023506899A (ja) 2023-02-20

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CTXT PTY LTD

Free format text: FORMER NAME(S): CTXT PTY LIMITED